

INDEX

A

- Active immunotherapy248
- Adaptive immune response.....317
- Adenosine-5'-Triphosphate (ATP)..... 17, 23, 299, 300, 317
- Adoptive cell therapy.....349
- Antibody.....vi, 49, 53, 67, 68, 75, 78, 90, 95–97, 99, 109,
121–124, 126, 129, 138, 144, 148, 150, 152–155,
179–182, 184–187, 204–208, 212, 222, 228, 238,
242, 250, 252, 254–257, 270, 276, 277, 280, 288,
289, 321–323, 326–328, 330, 335, 337, 344, 349,
350, 355, 356
- Antibody fragment 336, 337, 340, 349, 350
- Antibody-dependent cell-mediated cytotoxicity
(ADCC) 138, 270, 276, 336
- Anticancer vaccine..... vi, 317
- Antitumor immunity299
- Azoxymethane (AOM) 190, 192, 194–196,
200, 201

B

- B16 melanoma cells 52, 54, 163
- Blocking antibodies 50, 126, 138, 155, 181, 336, 339,
344, 346

C

- Calreticulin298, 317
- Cancer
 - immunosurveillancev, 87–115, 131, 132,
161–175, 269, 274–275, 277, 278, 297, 299
 - immunotherapy15, 43, 88, 190, 247, 269,
335, 337, 344, 349, 354, 356–358
- CD107a v, 88, 119–129
- CD47 317, 323, 336, 339, 342–345
- Cell isolation87–115, 121–123, 128, 136, 143,
152, 159, 177, 179, 189–201, 248, 251, 252, 271,
280, 341
- CellSearch®249, 253–254, 256, 258
- Cellular heterogeneity215
- Cellular senescence259, 260
- Checkpoint inhibitor 2, 284, 335
- Chemotaxis..... 98, 280, 299
- Chimeric antigen receptor (CAR).....270, 349–355, 358
- Chimeric antigen receptor T (CAR-T)vi, 43, 270,
271, 277, 278, 280, 349, 354, 356–358

- Circulating tumor cells (CTCs)..... vi, 247, 253, 256
- Colitis-associated cancer (CAC) 189–201
- Conditional cell ablation 162
- Conditional gene targeting 161, 162
- Cre recombinase 162, 164–169
- Cryopreserved.... 21, 22, 53, 107, 216, 219, 220, 227, 228, 328
- CXCL12270, 273–275, 278, 280
- Cytofluorimetric analysis.....87
- Cytokines45, 48, 50, 51, 73, 87–90, 95, 98, 99,
103, 104, 106, 110, 120, 132, 163, 190, 201, 298,
299, 321, 327, 331, 350, 352, 357, 358
- Cytometry by time-of-flight (CyTOF) 216, 224, 227
- Cytotoxicity v, 98, 100, 112, 120, 131–138, 148, 201,
270, 278, 309, 310, 322, 329, 350, 352, 355
- Cytotoxic T lymphocytes (CTL).....v, 43–54, 184, 300,
311, 322, 328, 329

D

- Dendritic cells (DC).....199, 299, 317–331
- Density gradient ultracentrifugation.....232, 234, 235,
240, 241, 244
- Dextran sodium sulfate (DSS)..... 190–192,
194–196, 200, 201
- Differentiation..... 2, 15, 29, 44, 49, 87, 91–93, 95,
102–106, 113, 203, 319, 321, 325–328, 331
- Digital PCR 11
- Disseminated tumor cells132
- Dormancy.....141

E

- Epithelial cells197, 198, 216, 225, 229, 257
- Epithelial-mesenchymal transition (EMT)248
- Epstein-Barr virus (EBV)58–64, 66, 68, 69
- Exome-sequencing 204, 211
- Exosomes..... v, 231, 233–237

F

- Flow cytometry 2, 3, 49, 50, 52, 61, 64–67, 75,
89, 90, 92, 95–100, 102, 103, 109, 113–115,
120–122, 124–126, 128, 132, 135–137, 147, 148,
152, 153, 158, 163, 177–183, 185, 187, 198–201,
216, 223, 224, 237–239, 242–244, 260, 271,
273–280, 305, 306, 310, 320–324, 330, 339,
343–346, 350, 354, 355

Fluorescence-activated cell sorting (FACS)..... 47, 53,
 74, 75, 77, 78, 88, 94, 100, 108, 111, 122, 124,
 133, 135, 149, 152, 173, 177, 179–182, 184–186,
 239, 243, 303, 305, 338, 339, 341, 343, 352,
 354, 355

Fluorophores153, 155, 158, 159, 182, 187,
 200, 253, 257, 261

Formalin-Fixed Paraffin Embedded (FFPE) tissue 216,
 218–221, 223, 228

H

High mobility group box-1 (HMGB1) 266, 299, 300, 317,
 320, 324

High throughput sequencing..... vi, 15–31

HLA peptidomicsvi, 204, 212

Humanized mice57

I

ImageStream X.....260–262, 264, 266

Imaging flow cytometry 232, 238, 242, 321, 322

Immune cells
 development74
 infiltrate284
 infiltration.....215, 269, 270, 273–275, 278, 280

Immune checkpoint..... v, 74, 336, 337

Immuno-evasion247

Immunogenic cell death (ICD) vi, 297–311, 317, 318,
 320, 322–324, 330

Immunosurveillancev, 59, 62, 87–115, 132, 141–150,
 161–175, 190, 269, 274–275, 277, 278, 317–331

Immunotherapyvi, 15, 43, 58, 59, 190, 193, 201,
 203, 247, 248, 269, 270, 284, 318, 320, 335, 337,
 344, 349, 354, 356–358

Innate lymphoid cells (ILCs) v, 73–75, 77–78,
 85, 102, 162

Intercellular communication.....231

Intraepithelial lymphocytes (IELs).....195–201

In vivo bioluminescent imaging.....174

L

Lamina propria (LP)195–198

Lamina propria mononuclear cells (LPMCs).....195–201

Latency competent cancer (LCC) cells 142, 143,
 145–150

Lentiviral gene transfer..... 350, 351

Leukemia.....121, 126, 128, 133, 231, 349

Live imaging..... 156, 157, 160

Luciferase145, 157, 159, 160, 163, 166, 174, 276, 280

Lung cancer..... 106, 302

Lymphomas..... 10, 58, 59, 270, 271, 276, 319, 330, 336, 349

M

Magnetic bead enrichment 152, 153

Mass cytometryv, 115, 215, 225, 226

Mass spectrometry.....vi, 203–213, 243

Maturation 3, 87, 88, 102, 104, 299, 319

Melanoma 16, 44, 45, 51, 52, 54, 158, 166,
 203, 212, 284, 298, 302

Metastasis..... 132, 148, 163, 190

Metastatic latency..... 141–150

MHC peptides 204–206, 208–211

Migration 2, 99, 100, 110, 111, 284, 289, 291

Myeloid effector function 151–153, 158, 180,
 184, 225, 298

N

Natural killer (NK) cells v, 67, 73, 87–115, 119–121,
 125, 126, 128, 129, 131–138, 141–150, 162–164,
 199, 259, 270, 273, 276, 280

Natural killer group 2, member D (NKG2D)..... 103, 104,
 112, 119, 121–123, 125, 126, 129, 131, 132, 135

Neo-antigens203–213

Notch signaling44

O

Orthotopic co-injection..... 152

P

Pluripotent stem cellsv, 43–54

Precursorsv, 73–115

Premalignant lesion259

Programmed cell death-1 (PD-1) 63, 67, 74, 270,
 271, 276, 277, 284

Programmed cell death-ligands 1 (PD-L1)..... 58, 247–250,
 252, 253, 255, 256, 270, 271, 274, 277, 297

Purification..... 20, 23, 27, 76, 80–81, 85, 102–103,
 107, 115, 152, 154–155, 197, 204, 205, 207, 208,
 210, 231, 337, 338, 342

Q

Quantificationv, 1–13, 152, 156, 160, 177, 241,
 252, 253, 260, 264, 265, 276, 278

S

ScreenCell®248, 250–251, 257

Senescence-associated beta-galactosidase
 (SA-β-gal)260–266

Signaling.....v, 143, 163, 215, 238, 249, 285, 299, 349, 350

Single-cell RNA sequencing (scRNA-seq)v, 73–86

Slice culturev, 283, 290, 292, 293

T

T cell
 exclusion 2, 100, 101
 receptorsvi, 2–5, 9, 10, 12, 15–31, 44, 47,
 50, 59, 67, 204, 274, 276, 349
TCR rearrangements2–3
 Tissues..... 1, 2, 9, 16, 21, 22, 29, 46, 52, 53, 58–61,
 64–66, 68, 73, 77, 87, 88, 91, 93, 106–107, 114,
 115, 146, 147, 149, 151–154, 157, 159, 163, 171,
 174, 175, 177, 180, 186, 190, 193, 197, 204, 209,
 215, 247, 259–261, 266, 284–289, 291, 292, 298
 Tool16, 74, 77, 87–115, 161–175, 177, 178, 190,
 265, 283, 290, 292, 293

Tumor immunosuppression248
 Tumor immunosurveillance 59, 87–115, 132, 161–175,
 190, 269, 274–275, 277, 278, 297, 299
 Tumor immunotherapy57
 Tumor infiltrating lymphocytes (TIL) 16, 52, 53, 203
 Tumor microenvironment (TME) v, 73, 177–188,
 248, 298, 299
 Tumor monitoring.....301
 Tumor-associated macrophages (TAMs).....v, 151–160
 Tumor-stroma spheroidsv, 269, 274–275, 277, 278
 Two-compartment bioreactor 232, 233, 239

V

Vaccination vi, 300, 301, 304, 306–308, 311, 317–331